Cisplatin and emesis

Aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin

Richard J. Gralla, Cindy Rittenberg, Mel Peralta, Linda Lettow, Michele Cronin

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The marked progress in controlling emesis caused by cisplatin characterizes the current status of antiemetic treatment for all chemotherapy. Cisplatin has provided a model for antiemetic studies. Strategies for controlling cisplatin-induced emesis are at least as successful when applied to other chemotherapy, and persistent problems such as delayed emesis and the emesis associated with consecutive-day chemotherapy are also similar to or less severe than those observed with cisplatin. The purpose of this report is twofold: first to outline briefly therapy for cisplatin-induced emesis as illustrated by several new studies, and, second, to report on a new trial that incorporates some different strategies in the control of delayed emesis after cisplatin.

Original languageEnglish (US)
Pages (from-to)86-91
Number of pages6
JournalONCOLOGY (United States)
Volume53
Issue numberSUPPL. 1
StatePublished - Jun 1996
Externally publishedYes

Fingerprint

Ondansetron
Dexamethasone
Cisplatin
Vomiting
Antiemetics
Drug Therapy
Therapeutics

Keywords

  • Cisplatin
  • Delayed emesis
  • Dexamethasone
  • Ondansetron

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cisplatin and emesis : Aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin. / Gralla, Richard J.; Rittenberg, Cindy; Peralta, Mel; Lettow, Linda; Cronin, Michele.

In: ONCOLOGY (United States), Vol. 53, No. SUPPL. 1, 06.1996, p. 86-91.

Research output: Contribution to journalArticle

@article{e35212c8d9384848b547f4b0f1859708,
title = "Cisplatin and emesis: Aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin",
abstract = "The marked progress in controlling emesis caused by cisplatin characterizes the current status of antiemetic treatment for all chemotherapy. Cisplatin has provided a model for antiemetic studies. Strategies for controlling cisplatin-induced emesis are at least as successful when applied to other chemotherapy, and persistent problems such as delayed emesis and the emesis associated with consecutive-day chemotherapy are also similar to or less severe than those observed with cisplatin. The purpose of this report is twofold: first to outline briefly therapy for cisplatin-induced emesis as illustrated by several new studies, and, second, to report on a new trial that incorporates some different strategies in the control of delayed emesis after cisplatin.",
keywords = "Cisplatin, Delayed emesis, Dexamethasone, Ondansetron",
author = "Gralla, {Richard J.} and Cindy Rittenberg and Mel Peralta and Linda Lettow and Michele Cronin",
year = "1996",
month = "6",
language = "English (US)",
volume = "53",
pages = "86--91",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Cisplatin and emesis

T2 - Aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin

AU - Gralla, Richard J.

AU - Rittenberg, Cindy

AU - Peralta, Mel

AU - Lettow, Linda

AU - Cronin, Michele

PY - 1996/6

Y1 - 1996/6

N2 - The marked progress in controlling emesis caused by cisplatin characterizes the current status of antiemetic treatment for all chemotherapy. Cisplatin has provided a model for antiemetic studies. Strategies for controlling cisplatin-induced emesis are at least as successful when applied to other chemotherapy, and persistent problems such as delayed emesis and the emesis associated with consecutive-day chemotherapy are also similar to or less severe than those observed with cisplatin. The purpose of this report is twofold: first to outline briefly therapy for cisplatin-induced emesis as illustrated by several new studies, and, second, to report on a new trial that incorporates some different strategies in the control of delayed emesis after cisplatin.

AB - The marked progress in controlling emesis caused by cisplatin characterizes the current status of antiemetic treatment for all chemotherapy. Cisplatin has provided a model for antiemetic studies. Strategies for controlling cisplatin-induced emesis are at least as successful when applied to other chemotherapy, and persistent problems such as delayed emesis and the emesis associated with consecutive-day chemotherapy are also similar to or less severe than those observed with cisplatin. The purpose of this report is twofold: first to outline briefly therapy for cisplatin-induced emesis as illustrated by several new studies, and, second, to report on a new trial that incorporates some different strategies in the control of delayed emesis after cisplatin.

KW - Cisplatin

KW - Delayed emesis

KW - Dexamethasone

KW - Ondansetron

UR - http://www.scopus.com/inward/record.url?scp=0029788232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029788232&partnerID=8YFLogxK

M3 - Article

VL - 53

SP - 86

EP - 91

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - SUPPL. 1

ER -